ATS (ATS) Tops Q1 Earnings and Revenue Estimates
- ATS (ATS) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.37 per share a year ago.
- 08/07/2025
|
ATS Reports First Quarter Fiscal 2026 Results
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three months ended June 29, 2025. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. First quarter highlights: Revenues increased 6.1% year over year to $736.7 million. Net income was $24.3 million compared to $35.3 million a year ago. Basic earnings per share were 25 cents, compared to 36 cents a.
- 08/07/2025
|
Analysts Estimate ATS (ATS) to Report a Decline in Earnings: What to Look Out for
- ATS (ATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/31/2025
|
ATS Announces Dates of First Quarter Results Conference Call and Annual Meeting of Shareholders
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the first quarter ended June 29, 2025, before markets open on Thursday August 07, 2025. At 8:30 a.m. Eastern on August 07, 2025, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/857742136 an.
- 07/23/2025
|
ATS Announces CEO Departure
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider will be stepping down from his role as Chief Executive Officer of the Company and from its Board of Directors (the “Board”) to pursue a new leadership opportunity outside the automation industry. The effective date for Mr. Hider's departure from the Company is expected to be by the end of August on a date to be determined by the Board. As a result of the foregoi.
- 07/07/2025
|
ATS to Participate in the Stifel 2025 Cross Sector Insight Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Stifel 2025 Cross Sector Insight Conference in Boston, MA on June 3, 2025. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Stifel representative or dgalison@atsautomation.com. About ATS Corporation ATS Corpora.
- 05/29/2025
|
ATS Corporation (ATS) Q4 2025 Earnings Call Transcript
- ATS Corporation (NYSE:ATS ) Q4 2025 Results Conference Call May 28, 2025 6:00 PM ET Company Participants David Galison - Head of Investor Relations Andrew Hider - Chief Executive Officer Ryan McLeod - Chief Financial Officer Conference Call Participants Cherilyn Radbourne - TD Cowen Maxim Sytchev - National Bank Sabahat Khan - RBC Capital Markets David Ocampo - Cormark Securities Michael Glen - Raymond James Operator Welcome to the ATS Corporation Fourth Quarter Conference Call and Webcast. This call is being recorded on May 28, 2025, at 6:00 p.m.
- 05/29/2025
|
ATS (ATS) Beats Q4 Earnings Estimates
- ATS (ATS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.48 per share a year ago.
- 05/28/2025
|
ATS Reports Fourth Quarter and Fiscal 2025 Results
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three and twelve months ended March 31, 2025. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. Fourth quarter highlights: Previously disclosed preliminary fourth quarter 2025 results are unchanged, except that the before tax-impact of the EV customer settlement in the amount of $171.1 million is.
- 05/28/2025
|
ATS Announces Settlement with EV Customer, Preliminary Fourth Quarter 2025 Results and Fourth Quarter Earnings Call
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today announced that it has reached a settlement agreement (the “Agreement”) with its Electric Vehicle (“EV”) customer with respect to the previously disclosed outstanding payments owed. Under the terms of the Agreement, the Company will receive payment from the customer of USD $134.75 million (approximately $194 million at the year end exchange rate) in the first quarter of fiscal 2026, with no fu.
- 05/23/2025
|
ATS to Participate in the RBC Capital Markets Canadian Industrials Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”) today announced that Ryan McLeod, Chief Financial Officer will participate in the RBC Capital Markets Canadian Industrials Conference in Toronto on May 15, 2025. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your RBC Capital Markets representative or dgalison@atsautomation.com. About ATS Corporation ATS Corporation is an industry-leading.
- 04/14/2025
|
ATS (ATS) Moves 17.0% Higher: Will This Strength Last?
- ATS (ATS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 04/10/2025
|
New Strong Sell Stocks for March 14th
- ATS, ADV and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on March 14, 2025.
- 03/14/2025
|
New Strong Sell Stocks for March 10th
- ATS, AIRS and DIN have been added to the Zacks Rank #5 (Strong Sell) List on March 10, 2025.
- 03/10/2025
|
ATS to Participate in the J.P. Morgan Industrials Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the J.P. Morgan Industrials Conference in New York City, NY on March 11, 2025. ATS is scheduled to host a fireside chat at the event at 09:45 a.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomation.com/ in the.
- 02/18/2025
|
Is the Options Market Predicting a Spike in ATS Corporation (ATS) Stock?
- Investors need to pay close attention to ATS Corporation (ATS) stock based on the movements in the options market lately.
- 02/11/2025
|
New Strong Sell Stocks for February 11th
- ATS, CNMD and CSX have been added to the Zacks Rank #5 (Strong Sell) List on February 11, 2025.
- 02/11/2025
|
ATS Corporation. (ATS) Q3 2025 Earnings Call Transcript
- ATS Corporation. (NYSE:ATS ) Q3 2025 Earnings Conference Call February 5, 2025 8:30 AM ET Company Participants David Galison - Head of Investor Relations Andrew Hider - Chief Executive Officer Ryan McLeod - Chief Financial Officer Conference Call Participants Justin Keywood - Stifel Cherilyn Radbourne - TD Cowen Patrick Baumann - J.P.
- 02/05/2025
|
ATS (ATS) Matches Q3 Earnings Estimates
- ATS (ATS) came out with quarterly earnings of $0.23 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.48 per share a year ago.
- 02/05/2025
|
ATS Reports Third Quarter Fiscal 2025 Results
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three and nine months ended December 29, 2024. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. Third quarter highlights: Revenues were $652.0 million compared to $752.0 million a year ago. Net income was $6.5 million compared to $47.2 million a year ago. Basic earnings per share were 7 cents, co.
- 02/05/2025
|
Earnings Preview: ATS (ATS) Q3 Earnings Expected to Decline
- ATS (ATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/29/2025
|
ATS to Participate in the Raymond James 46th Annual Institutional Investors Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Raymond James 46th Annual Institutional Investors Conference in Orlando, FL on March 5, 2025. ATS is scheduled to host a fireside chat at the event at 9:50 a.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsauto.
- 01/27/2025
|
ATS To Host Third Quarter Earnings Call Wednesday February 5, 2025, at 8:30 a.m. Eastern
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the third quarter ended December 29, 2024, before markets open on Wednesday February 5, 2025. At 8:30 a.m. Eastern on February 5, 2025, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/53603.
- 01/23/2025
|
ATS to Participate in the Barclays Industrials Select Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Barclays Industrials Select Conference in Miami, FL on February 20, 2025. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Barclays representative or dgalison@atsautomation.com. About ATS Corporation ATS Corporati.
- 01/20/2025
|
ATS to Participate in the Citi Global Industrial Tech and Mobility Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Citi Global Industrial Tech and Mobility Conference in Miami, FL on February 19, 2025. ATS is scheduled to host a fireside chat at the event at 3:30 p.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomation.
- 01/20/2025
|
ATS Announces Closing Of Additional $200 Million Senior Notes Offering
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) confirmed today that it has successfully closed its previously announced private placement offering (the “Offering”) of C$200 million aggregate principal amount of 6.50% senior unsecured notes due August 21, 2032 (the “Notes”). The Notes have identical terms and will be fungible (following the expiry of the applicable statutory hold period) with, and are a part of a single series with, the $400.
- 12/19/2024
|
ATS Announces Offering and Pricing of Upsized Reopening of $200 Million Senior Notes Due 2032
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”), announced today that it has entered into an underwriting agreement with a syndicate of underwriters to sell, pursuant to a private placement offering (the “Offering”), an additional $200 million aggregate principal amount of its 6.50% senior unsecured notes due 2032 (the “Notes”), which aggregate principal amount of additional Notes was upsized from the initial target reopening size of $150 millio.
- 12/16/2024
|
ATS Corporation Releases FY2024 Sustainability Report
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today released its FY2024 Sustainability Report, for the period ending March 31, 2024. This report, titled Future in Focus, is the Company's fifth annual report and provides updates and additional insight into ATS' work in the area of sustainability. The full report is available on the ATS website. About ATS Corporation ATS Corporation is an industry-leading automation solutions provider to many.
- 12/16/2024
|
ATS Announces Normal Course Issuer Bid
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”), today announced that the Toronto Stock Exchange (“TSX”) has accepted a notice filed by it of its intention to make a normal course issuer bid (“NCIB”). As of December 2, 2024, ATS had a total of 97,926,826 common shares issued and outstanding. Under the NCIB, ATS will have the ability to purchase for cancellation up to a maximum of 8,259,180 common shares, representing approximately 10% of the pub.
- 12/12/2024
|
New Strong Sell Stocks for December 2nd
- ATI, ATS and AGL have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2024.
- 12/02/2024
|
ATS Corporation (ATS) Q2 2025 Earnings Call Transcript
- ATS Corporation. (NYSE:ATS ) Q2 2025 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants David Galison - Head of Investor Relations Andrew Hider - Chief Executive Officer Ryan McLeod - Chief Financial Officer Conference Call Participants Sabahat Khan - RBC Justin Keywood - Stifel David Ocampo - Cormark Securities Patrick Sullivan - TD Cowen Maxim Sytchev - National Bank Financial Michael Glen - Raymond James Patrick Baumann - JPMorgan Operator Welcome to the ATS Corporation Second Quarter Conference Call and Webcast.
- 11/06/2024
|
ATS (ATS) Lags Q2 Earnings and Revenue Estimates
- ATS (ATS) came out with quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.46 per share a year ago.
- 11/06/2024
|
ATS Reports Second Quarter Fiscal 2025 Results
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three and six months ended September 29, 2024. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. Second quarter highlights: Revenues decreased 16.7% year over year to $612.8 million. Net loss was $0.9 million compared to net income of $50.7 million a year ago. Basic earnings (loss) per share were.
- 11/06/2024
|
ATS to Participate in the UBS Global Industrials and Transportation Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”), today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the UBS Global Industrials and Transportation Conference in Manalapan, FL on December 04, 2024. ATS is scheduled to host a fireside chat at the event at 8:00 a.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautom.
- 11/04/2024
|
Analysts Estimate ATS (ATS) to Report a Decline in Earnings: What to Look Out for
- ATS (ATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/30/2024
|
ATS To Host Second Quarter Earnings Call Wednesday November 6, 2024, at 8:30 a.m. Eastern
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the second quarter ended September 29, 2024, before markets open on Wednesday November 6, 2024. At 8:30 a.m. eastern November 6, 2024, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/775172.
- 10/29/2024
|
ATS to Participate in the Scotiabank Transportation & Industrials Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Scotiabank Transportation & Industrials Conference in Toronto on November 13, 2024. ATS is scheduled to host a fireside chat at the event at 2:00 p.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomat.
- 10/16/2024
|
ATS to Participate in the Baird 2024 Global Industrial Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Baird 2024 Global Industrial Conference in Chicago on November 12, 2024. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Baird representative or dgalison@atsautomation.com. About ATS Corporation ATS Corporatio.
- 10/16/2024
|
New Strong Sell Stocks for October 4th
- ATS, AZUL and BBC have been added to the Zacks Rank #5 (Strong Sell) List on October 4, 2024.
- 10/04/2024
|
New Strong Sell Stocks for September 30th
- ATS, AZUL and BW have been added to the Zacks Rank #5 (Strong Sell) List on September 30, 2024.
- 09/30/2024
|
ATS Corporation: Diamond In The Rough
- ATS provides vertically integrated automation solutions, focusing on Life Sciences and F&B sectors, with a robust backlog and strategic acquisitions enhancing growth potential. The macroeconomic environment, including lower interest rates and demographic changes, supports ATS's growth, especially in reshoring economies and increasing efficiency demands. Despite a healthy balance sheet, ATS faces risks from supply chain issues and cyclical industry exposure, with upcoming restructuring costs impacting short-term performance.
- 09/26/2024
|
New Strong Sell Stocks for September 13th
- ATS, BMTX and B have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2024.
- 09/13/2024
|
ATS to Participate in the Jefferies Industrials Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Jefferies Industrials Conference in New York City, NY on September 5, 2024. ATS is scheduled to host a fireside chat at the event at 2:30 p.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomation.com/ in.
- 08/19/2024
|
ATS Corporation: This High-Quality Compounder Is A Bargain At 16x Earnings
- ATS Corporation is a play on automation growth in manufacturing with exposure to electric vehicle battery outsourcing. The stock is down ~40% from its peak, but has potential for over 50% upside in a couple of years. Recent earnings show a slight EPS miss, but strong order bookings and backlog growth in non-transportation segments.
- 08/19/2024
|
ATS Corporation: Near Record Bookings In Q3 (Rating Upgrade)
- ATS Corporation is a developer of automation technology with global operations and $3 billion in annual sales. Recent results showed a decline in revenue but strong performance in life sciences, with a record backlog of $990 million. Despite short-term challenges, ATS's strategic investments in life sciences and attractive valuation make it a compelling investment opportunity.
- 08/13/2024
|
ATS Corporation (ATS) Q1 2025 Earnings Call Transcript
- ATS Corporation (NYSE:ATS ) Q1 2025 Results Conference Call August 8, 2024 8:30 AM ET Company Participants David Galison - Head of Investor Relations Andrew Hider - Chief Executive Officer Ryan McLeod - Chief Financial Officer Conference Call Participants Michael Glen - Raymond James Patrick Sullivan - TD Cowen Joe Ritchie - Goldman Sachs Justin Keywood - Stifel Maxim Sytchev - National Bank Financial David Ocampo - Cormark Securities Patrick Baumann - JPMorgan Operator Hello, everyone, and welcome to the ATS Corporation First Quarter Conference Call and Webcast. This call is being recorded on August 8, 2024 at 8:30 a.m.
- 08/10/2024
|
ATS (ATS) Lags Q1 Earnings Estimates
- ATS (ATS) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.51 per share a year ago.
- 08/08/2024
|
Earnings Preview: ATS (ATS) Q1 Earnings Expected to Decline
- ATS (ATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/01/2024
|
ATS Announces Dates of First Quarter Results Conference Call and Annual Meeting of Shareholders
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the first quarter ended June 30, 2024, before markets open on Thursday August 8, 2024. At 8:30 a.m. eastern August 8, 2024, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/283321487, and th.
- 07/22/2024
|
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
- St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), presented positive results from its Phase 2, proof-of-concept, Controlled Human Infection Model (CHIM) study in which healthy volunteers were challenged with influenza virus following administration of Neumifil. These data were featured during an oral presentation* at the American Thoracic Society (ATS) in San Diego on 21st May.
- 05/23/2024
|
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
- KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting
- 05/22/2024
|
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
- JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego.
- 05/21/2024
|
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
- Dupixent ® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024.
- 05/20/2024
|
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
- NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
- 05/20/2024
|
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
- PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference. Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE (sRAGE) concentration in bronchoalveolar lavage fluid (BALF) and serum in a dose-dependent manner in normal healthy volunteers (NHV) and in patients with mild to moderate asthma. “These results underscore the potential of our proprietary TRiMTM platform to enable us to develop impactful new therapies to potentially treat multiple pulmonary diseases with significant unmet needs. Arrowhead was the first company to show that RNAi could be harnessed to achieve high levels of target gene knockdown in the lung in healthy human subjects and these data presented at ATS 2024 build on that success,” said James Hamilton, M.D., chief of discovery and translational medicine at Arrowhead. “Our ARO-RAGE data is first-in-class and demonstrated deep and sustained knockdown in the lung in patients with mild to moderate asthma, a long duration of effect that appears to support every two-month dosing, and a favorable safety and tolerability profile. These results give us further confidence as we move towards the initiation of a Phase 2 study in late 2024.” Select ARO-RAGE Results In the ongoing 1001 study, ARO-RAGE achieved the following key results as of 05 April 2024: Single and multiple doses of ARO-RAGE in NHVs led to dose dependent reductions in sRAGE in both BALF and in serum After two doses of ARO-RAGE in patients with mild to moderate asthma, serum sRAGE was reduced up to 88% with a mean maximum reduction up to 77% Serum sRAGE was reduced in a dose-responsive manner with similar reductions observed in NHVs and patients with asthma at each dose level Pharmacodynamic effects were long lasting, with a duration that appears to support once every two-month dosing ARO-RAGE plasma exposure following a single dose in NHVs was of limited quantity and duration Safety and Tolerability Results ARO-RAGE has shown a favorable safety profile to date, with no demonstrated pattern of effect on systemic safety labs and no demonstrated pattern of detrimental effect on lung function (FEV1, FVC, or DLCO) over time. There have been no serious adverse effects related to study drug and no treatment emergent adverse events leading to trial withdrawal or study drug discontinuation. Arrowhead also presented preclinical data on two additional lung targeted programs that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform. ARO-TSLP is designed to silence the epithelial cytokine thymic stromal lymphopoietin (TSLP), a genetically and clinically validated therapeutic target that activates multiple immune cell lineages to promote asthmatic inflammation. ARO-IAV is designed to silence expression of highly conserved influenza A viruses, including the highly pathogenic avian influenza virus (H5N1). Details about the ATS presentations are listed below. American Thoracic Society (ATS) 2024 International Conference – May 17-22, 2024 Title: A First-in-Human Study of ARO-RAGE, a Novel Inhaled RNA-Interference Therapy for Asthma Date/Time: May 19, 2024, 11:30 a.m. PDT Type: Late-Breaking Poster Title: A lung-targeted therapeutic siRNA against highly conserved viral M1 mRNAs effectively limits highly pathogenic influenza A infection in mice Date/Time: May 20, 2024, 11:30 a.m. PDT Type: Poster Title: Lung-targeted RNAi molecules silence human TSLP expression in PCLS cultures and humanized mice and suppress pulmonary allergic inflammation Date/Time: May 20, 2024, 11:30 a.m. PDT Type: Poster Presentation materials may be accessed on the Events and Presentations page in the Investors section of the Arrowhead website. About Pulmonary TRiMTM Platform Arrowhead’s pulmonary Targeted RNAi Molecule (TRiMTM) delivery platform facilitates selective delivery of therapeutic small interfering RNAs (siRNAs) to the lung epithelium via an integrin αvβ6 targeting moiety, mediating durable gene silencing upon inhalation utilizing a nebulizer. About ARO-RAGE ARO-RAGE is an investigational RNAi therapeutic targeting the receptor for advanced glycation end-products (RAGE) as a potential treatment for inflammatory lung diseases. RAGE is implicated as an upstream mediator of Type-2 and non-Type-2 inflammatory cascades and is involved in the pathogenesis of asthma and numerous inflammatory diseases1,2,3. Silencing RAGE expression via RNAi is designed to reduce the amount of RAGE protein expressed on pulmonary epithelial cells. Reduced RAGE expression in the pulmonary epithelium may result in reduction of RAGE-dependent inflammatory pathways, leading to decreased exacerbation frequency and improved airflow in patients with asthma. About the ARORAGE-1001 Phase 1/2 Study ARORAGE-1001 (NCT05276570) is an ongoing Phase 1/2a, randomized, double-blinded, placebo-controlled study in normal healthy volunteers (NHV) (Part 1), in patients with mild to moderate asthma (Part 2), and in patients with high baseline fractional exhaled nitric oxide (FeNO) (Part 3). Subjects receive ascending doses of ARO-RAGE or placebo via nebulizer on Day 1 in the single-ascending dose cohorts or Days 1 and 29 in the multiple-ascending dose cohorts. The objectives of the study include the assessment of safety and tolerability, pharmacokinetics, and pharmacodynamics of ARO-RAGE in NHVs and patients with asthma. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma or on LinkedIn. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts. Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. ________________ 1. Perkins TN. Allergy 2021;76:1350-66. 2. Oczypok EA. JACI 2015;136:747-56. 3. Killian KN. Front Immunol 2023;14:1039997.
- 05/20/2024
|
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
- WILMINGTON, Del.--(BUSINESS WIRE)--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen's TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to pl.
- 05/19/2024
|
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
- Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels THOUSAND OAKS, Calif. , May 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status.
- 05/19/2024
|
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego, CA. Savara's partner, Trillium Health LLC, presented a poster on the laboratory blood test that was recently developed to aid in the diagnosis of aPAP. Below are summaries of the posters presented: Poste.
- 05/19/2024
|
ATS to Participate in Deutsche Bank's Global Industrials, Materials & Building Products Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Ryan McLeod, Chief Financial Officer will participate in Deutsche Bank's 15th Annual Global Industrials, Materials & Building Products Conference in New York, NY on June 5, 2024. ATS is scheduled to host a fireside chat at the event at 9:20 a.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomation.com/.
- 05/17/2024
|
ATS to Participate in the Stifel 2024 Cross Sector Insight Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Stifel 2024 Cross Sector Insight Conference in Boston, MA on June 4, 2024. ATS is scheduled to host a fireside chat at the event at 9:10 a.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomation.com/ in t.
- 05/17/2024
|
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
- SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024 Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research: 26 ResMed-supported abstracts will be presented at ATS. Full list below.
- 05/16/2024
|
ATS Corporation (ATS) Q4 2024 Earnings Call Transcript
- ATS Corporation (NYSE:ATS ) Q4 2024 Earnings Conference Call May 16, 2024 8:30 AM ET Company Participants David Galison - Head of Investor Relations Andrew Hider - Chief Executive Officer Ryan McLeod - Chief Financial Officer Conference Call Participants David Ocampo - Cormark Securities Michael Doumet - Scotiabank Joe Ritchie - Goldman Sachs Michael Glen - Raymond James Justin Keywood - Stifel Patrick Baumann - JPMorgan Maxim Sytchev - National Bank Financial Cherilyn Radbourne - TD Securities Operator Welcome to the ATS Corporation Fourth Quarter Conference Call and Webcast. This call is being recorded on May 16th, 2024 at 8:30 A.M.
- 05/16/2024
|
ATS (ATS) Q4 Earnings and Revenues Top Estimates
- ATS (ATS) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.54 per share a year ago.
- 05/16/2024
|
ATS Reports Fourth Quarter and Annual 2024 Results
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”) today reported its financial results for the three and twelve months ended March 31, 2024. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. Fourth quarter highlights: Revenues increased 8.3% year over year to $791.5 million. Net Income was $48.5 million compared to $29.6 million a year ago. Basic earnings per share were 49 cents, compared t.
- 05/16/2024
|
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
- THOUSAND OAKS, Calif. , May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m.
- 05/15/2024
|
ATS To Acquire Packaging Machine Provider Paxiom
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) a leading automation solutions provider, today announced it has entered into a definitive agreement to acquire Paxiom Group (“Paxiom”), a provider of primary, secondary, and end-of-line packaging machines in the food and beverage, cannabis, and pharmaceutical industries. “With a dynamic product mix and a growing global footprint, Paxiom will be a great addition to ATS,” said Andrew Hider, Chief.
- 05/15/2024
|
ATS to Participate in TD Cowen's 2nd Annual Sustainability Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Ryan McLeod, Chief Financial Officer will participate in TD Cowen's 2nd Annual Sustainability Conference virtually on May 22, 2024. ATS is scheduled to host a fireside chat at the event at 2:55 p.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomation.com/ in the Events & Presentations section. A repla.
- 05/01/2024
|
ATS To Host Fourth Quarter Earnings Call Thursday May 16, 2024, at 8:30 a.m. Eastern
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the fourth quarter ended March 31, 2024, before markets open on Thursday May 16, 2024. At 8:30 a.m. eastern May 16, 2024, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed live at https://events.q4inc.com/attendee/680938193. The.
- 05/01/2024
|
ATS Announces C$163 Million Secondary Offering of Common Shares
- CAMBRIDGE, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) has announced today that it has entered into an agreement with a fund managed by Mason Capital Management LLC (the “Selling Shareholder”) and Scotiabank (the “Underwriter”), acting as Sole Bookrunner, pursuant to which the Underwriter has agreed to purchase, on a bought deal basis, 3,500,000 common shares of ATS (the “Shares”) from the Selling Shareholder, at a price of C$46.55 per Share for gross proceeds to the Selling Shareholder of approximately C$163 million (the “Offering”). The Offering is expected to close on or about April 3, 2024 (the “Closing”).
- 03/27/2024
|
ATS to Participate in the Raymond James 45th Annual Institutional Investors Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Raymond James 45th Annual Institutional Investors Conference in Orlando, FL on March 6, 2024. ATS is scheduled to host a fireside chat at the event at 11:00 a.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.ats.
- 02/27/2024
|
ATS to Participate in the Citi Global Industrial Tech and Mobility Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Citi Global Industrial Tech and Mobility Conference in Miami, FL on February 21, 2024. ATS is scheduled to host a fireside chat at the event at 10:30 a.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomat.
- 02/12/2024
|
ATS to Participate in the Barclays Industrials Select Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Barclays Industrials Select Conference in Miami, FL on February 22, 2024. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Barclays representative or dgalison@atsautomation.com. About ATS Corporation ATS Corpor.
- 02/12/2024
|
ATS Corporation (ATS) Q3 2024 Earnings Call Transcript
- ATS Corporation (ATS) Q3 2024 Earnings Call Transcript
- 02/07/2024
|
ATS (ATS) Q3 Earnings Match Estimates
- ATS (ATS) came out with quarterly earnings of $0.48 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.38 per share a year ago.
- 02/07/2024
|
ATS Reports Third Quarter Fiscal 2024 Results
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”) today reported its financial results for the three and nine months ended December 31, 2023. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. Third quarter highlights: Revenues increased 16.2% year over year to $752.0 million. Net Income was $47.2 million compared to $29.2 million a year ago. Basic earnings per share were 48 cents, compared.
- 02/07/2024
|
ATS (ATS) Reports Next Week: Wall Street Expects Earnings Growth
- ATS (ATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/31/2024
|
ATS To Host Third Quarter Earnings Call Wednesday February 7, 2024, at 8:30 a.m. Eastern
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the third quarter ended December 31, 2023, before the TSX opens on Wednesday, February 7, 2024. At 8:30 a.m. eastern February 7, 2024, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed live at https://events.q4inc.com/attendee/4.
- 01/23/2024
|
5 Must-Buy Stocks as December Industrial Production Edges Up
- Manufacturing activity is gathering steam, which is helping stocks like ATS Corporation (ATS), Cintas Corporation (CTAS), Enerpac Tool Group Corp. (EPAC), A. O. Smith Corporation (AOS) and Lakeland Industries, Inc. (LAKE).
- 01/19/2024
|
Wall Street Analysts Predict a 27.33% Upside in ATS (ATS): Here's What You Should Know
- The average of price targets set by Wall Street analysts indicates a potential upside of 27.3% in ATS (ATS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 01/04/2024
|
ATS Announces Normal Course Issuer Bid
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”), today announced that the Toronto Stock Exchange (“TSX”) has accepted a notice filed by it of its intention to make a normal course issuer bid (“NCIB”). As of December 1, 2023, ATS had a total of 98,899,883 common shares issued and outstanding. Under the NCIB, ATS will have the ability to purchase for cancellation up to a maximum of 8,044,818 common shares, representing approximately 10% of the pub.
- 12/13/2023
|
ATS Completes Acquisition Of Avidity Science
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”), today announced the successful completion of its acquisition of Avidity Science, LLC ("Avidity"), a growing designer and manufacturer of automated water purification solutions for biomedical and life science applications. ATS entered into a definitive agreement and announced its intention to acquire Avidity on September 22, 2023. About ATS Corporation ATS Corporation is an industry-leading automat.
- 11/17/2023
|
ATS to Participate in the 2023 UBS Industrials Summit
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”), an industry-leading automation solutions provider, today announced that Ryan McLeod, Chief Financial Officer will participate in the 2023 UBS Industrials Summit in Palm Beach, FL on November 29, 2023. Management will be hosting institutional investor meetings, which can be arranged by contacting your UBS representative or dgalison@atsautomation.com. About ATS Corporation ATS Corporation is an indu.
- 11/16/2023
|
ATS to Participate in the 23rd Annual Scotiabank Transportation & Industrials Conference
- CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”), an industry-leading automation solutions provider, today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the 23rd Annual Scotiabank Transportation & Industrials Conference in Toronto on November 15, 2023. ATS is scheduled to host a fireside chat at the event at 12:45 p.m. Management will also host institutional investor meetings.
- 11/10/2023
|
ATS To Host Second Quarter Earnings Call Wednesday November 8, 2023, at 8:30 a.m. Eastern
- CAMBRIDGE, ON , Oct. 26, 2023 /PRNewswire/ - ATS Corporation (TSX: ATS) (NYSE: ATS) ("ATS" or the "Company") will report its financial results for the second quarter ended October 1, 2023, before the TSX opens on Wednesday November 8, 2023. At 8:30 a.m.
- 10/26/2023
|
ATS Corporation (ATS) Q1 2024 Earnings Call Transcript
- ATS Corporation (NYSE:ATS ) Q1 2024 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants David Galison - Head, Investor Relations Andrew Hider - Chief Executive Officer Ryan McLeod - Chief Financial Officer Conference Call Participants Patrick Sullivan - TD Cowen David Ocampo - Cormark Securities Michael Doumet - Scotiabank Justin Keywood - Stifel Sabahat Khan - RBC Capital Operator Welcome to the ATS Corporation First Quarter Conference Call and Webcast. This call is being recorded on August 9, 2023, at 8:30 a.m.
- 08/12/2023
|
ATS Corp: A Strong Contender in the Industrial Products Sector with Good Outperformance Potential
- ATS Corp ( ATS , Financial), a prominent player in the Industrial Products sector, is currently trading at $44.3 with a market capitalization of $4.38 billion. Despite a slight dip of 1.60% over the past four weeks, the stock has seen a gain of 5.75% today.
- 08/09/2023
|
ATS Announces Dates of First Quarter Results Conference Call and Annual & Special Shareholders' Meeting
- CAMBRIDGE, ON , July 25, 2023 /PRNewswire/ - ATS Corporation (TSX: ATS) (NYSE: ATS) ("ATS" or the "Company") will report its financial results for the first quarter ended July 3, 2023 before the TSX opens on Wednesday August 9, 2023. At 8:30 a.m.
- 07/25/2023
|
3 Growth Stocks Every Investor Should Know About Now
- With technology advancing at a breakneck speed, investors – having taken care of their core portfolio needs – should consider must-know growth stocks with their discretionary funds. Unlike blue-chip enterprises with long-established businesses, these expansion-oriented companies tend to be quite risky.
- 07/23/2023
|
Here are analysts' 20 favorite AI stocks — and they still see upside for Nvidia
- So far, 2023 has been the year of artificial intelligence in the stock market. Nvidia Corp. has been the poster child, with shares returning 178% this year with dividends reinvested.
- 06/27/2023
|
ATS Corp files for IPO on NYSE
- ATS Corporation (TSX:ATS) announced that it has launched an initial public offering (IPO) in the US, filing an application to list its common shares on the New York Stock Exchange (NYSE) under the symbol ‘ATS'. The Cambridge-Ontario provider of automation solutions said its stock is expected to begin trading on the NYSE following the pricing of the offering, but will continue to trade on the Toronto Stock Exchange (TSX) under the symbol ‘ATS'.
- 05/24/2023
|
